Clinical Trials: Page 145
-
Viiv's HIV combo drug recommended for approval by EMA advisers
It's likely the drug will become a formidable competitor to Gilead's Atripla.
By Nicole Gray • June 30, 2014 -
EU advisors recommend Avastin for refractory ovarian cancer
The drug will be used in combination with chemotherapy to improve outcomes.
By Nicole Gray • June 27, 2014 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
Boehringer's Pradaxa reversal drug gets breakthrough therapy status
The ability to reverse anticoagulation could help Pradaxa become the leading anticoagulant.
By Nicole Gray • June 27, 2014 -
Eisai files NDA for lenvatinib in Japan
Thyroid cancer affects up to 29,000 people in Japan.
By Nicole Gray • June 27, 2014 -
NICE recommends Invokana for diabetes
This is the 10th drug that NICE has recommended for treatment of type 2 diabetes.
By Nicole Gray • June 26, 2014 -
FDA
FDA requests additional information on AstraZeneca's ovarian cancer drug
The agency has concerns related to efficacy and safety.
By Nicole Gray • June 26, 2014 -
High-dose liraglutide may be the next weight-loss breakthrough
It decreases risk of progression to diabetes in individuals with pre-diabetes.
By Nicole Gray • June 26, 2014 -
Melanoma drug trial stopped early after positive results
The decision could cheer Bristol-Myers Squibb stockholders -- and the medical community.
By Nicole Gray • June 25, 2014 -
EMA grants orphan drug status to multiple myeloma treatment
Marizomib now has orphan drug status in the EU and the US.
By Nicole Gray • June 25, 2014 -
Roche applies for IND for idiopathic pulmonary fibrosis treatment
Erivedge was designated a breakthrough therapy for treatment of basal cell carcinoma.
By Nicole Gray • June 25, 2014 -
Bayer, Dimension Therapeutics collaborating on hemophilia A gene therapy
If the treatment makes it to market, it will be a major game-changer for patients.
By Nicole Gray • June 25, 2014 -
Inovio initiates early-stage clinical trials for cervical cancer drug
The candidate is part of the emerging class of immuno-oncologic drugs.
By Nicole Gray • June 25, 2014 -
Study: Heart disease, diabetes patients more likely to stay on statins
The survey also found heavy drinkers were far more likely to stop taking the medication.
By Randy Lilleston • June 24, 2014 -
Kala Pharma advances clinical testing of ocular drug
The nanotechnology-based drug is being evaluated for use in dry eye disease and perisurgical inflammation of the eye.
By Nicole Gray • June 24, 2014 -
MacroGenic moves into phase 1 with new leukemia drug
This first-in-class candidate has a dual mechanism of action.
By Nicole Gray • June 24, 2014 -
Boehringer Ingelheim stops development of hepatitis C drug
The company cites the competitive landscape as the determining factor.
By Nicole Gray • June 24, 2014 -
Sanofi, Merrimack continue development of molecular target found in many cancers
An extensive phase II clinical trial program is underway.
By Nicole Gray • June 22, 2014 -
Companies collaborate to fight multidrug-resistant pathogens
A new diagnostic test is available in Europe and coming to the U.S., but that's just the first step.
By Nicole Gray • June 22, 2014 -
NICE approves Effient for broader use
The product is now acceptable for treatment of many types of acute coronary syndrome.
By Nicole Gray • June 22, 2014 -
Sivextro approved for hard-to-treat skin infections
This is the second drug covered under the FDA's new Qualified Infectious Disease Program designation.
By Nicole Gray • June 22, 2014 -
Deep Dive
Theory can outrun reality on drug approval fast track
The designation can create a buzz that is often not justified.
By Nicole Gray • June 20, 2014 -
J&J rachets up R&D through 12 new alliances
The company has many collaborations underway.
By Nicole Gray • June 20, 2014 -
J&J acquires global rights to influenza drug
If approved, the vaccine would be a new treatment approach to an age-old viral condition.
By Nicole Gray • June 20, 2014 -
Takeda halts development of prostate cancer drug
Phase III trials showed increased progression-free survival, but no significant increases in overall survival.
By Nicole Gray • June 20, 2014 -
PhRMA highlights clinical development of drugs aimed at older Americans
For people over 65, 95% of healthcare spending is for chronic diseases.
By Nicole Gray • June 20, 2014
Previous
